Glucose B.Braun

Glucose B.Braun is an intravenous solution for injection that contains glucose monohydrate as the sole active ingredient. The product is supplied in a sterile liquid form, with the specific concentration not disclosed in the available data. Manufactured for the European market, it is classified as a prescription‑only medication and is used to provide an immediate source of glucose and to support fluid balance when administered intravenously.

Glucose B.Braun is indicated for clinical situations where rapid glucose supplementation or fluid replacement is required. It is commonly employed in hospital settings for the management of several conditions. - Treatment of hypoglycemia in patients who cannot take oral glucose. - Intravenous fluid and electrolyte replacement during dehydration or blood loss. - Component of parenteral nutrition regimens to meet caloric needs. - Osmotic agent to expand extracellular fluid volume in shock or sepsis. - Support of glucose levels during surgical procedures or anesthesia. - Management of electrolyte imbalances when combined with appropriate electrolyte solutions.

When administered intravenously, Glucose B.Braun can produce a range of physiological responses. Most patients experience mild, transient effects, while rare serious reactions may occur. These effects are generally dose‑dependent and related to the rapid change in plasma glucose and fluid volume. Common: - Transient hyperglycemia that resolves as glucose is metabolized. - Mild irritation or pain at the injection site. - Temporary increase in urine output due to osmotic diuresis. - Slight rise in serum sodium levels secondary to fluid shift. Serious: - Severe hypoglycemia if administered in excess after rapid glucose utilization. - Allergic reactions such as rash, itching, or anaphylaxis. - Fluid overload leading to pulmonary edema in susceptible patients. - Electrolyte disturbances, particularly hypernatremia, from rapid infusion.

Glucose B.Braun should be used with attention to patient‑specific factors and clinical circumstances to minimize risks. Healthcare professionals must assess the need for glucose replacement, monitor vital signs, and adjust infusion rates accordingly. - Verify blood glucose before administration to prevent over‑correction. - Adjust dose in patients with renal or hepatic impairment. - Monitor for fluid overload, especially in heart failure or pulmonary disease. - Use caution in individuals with known hypersensitivity to glucose solutions. - Ensure aseptic technique to avoid catheter‑related infections.

Glucose B.Braun may interact with other intravenous therapies or medications that affect glucose metabolism or fluid balance. Clinicians should review a patient’s medication list and infusion plan before initiating therapy. Avoid: - Co‑administration with rapid‑acting insulin boluses without glucose monitoring. - Simultaneous infusion of high‑volume hypertonic solutions that could precipitate fluid overload. Use with caution: - Concurrent use of diuretics, which may alter electrolyte status during glucose infusion. - Administration alongside catecholamines, as they can increase glucose utilization. - Combination with other carbohydrate‑containing parenteral nutrition components, requiring careful caloric calculation. - Concurrent use of beta‑blockers may mask hypoglycemia symptoms, requiring closer glucose monitoring.